BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Maintains $234 Price Target
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Kostas Biliouris maintains an Outperform rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a $234 price target.
June 24, 2024 | 5:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital analyst Kostas Biliouris has reaffirmed an Outperform rating for Alnylam Pharmaceuticals, maintaining a price target of $234.
The reaffirmation of an Outperform rating and a maintained price target of $234 by BMO Capital is a positive signal for investors, suggesting confidence in the company's future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100